scholarly journals PCN52 Treatment Patterns and Associated Costs of the Metastatic Prostate Cancer, Retrospective Data Base Analysis of the Brazilian Private Health Care System

2012 ◽  
Vol 15 (4) ◽  
pp. A217
Author(s):  
L.S.K. Bahmdouni ◽  
M.L. Pereira ◽  
O.A.C. Clark ◽  
E. Faleiros ◽  
A.P. Castro ◽  
...  
2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 361-361
Author(s):  
Justin Oake ◽  
Oksana Harasemiw ◽  
Navdeep Tangri ◽  
Thomas Ferguson ◽  
Jeff W. Saranchuk ◽  
...  

361 Background: A large body of research has shown that there are strong socioeconomic disparities in access to cancer treatment. However, whether these inequalities persist among men with prostate cancer has not been previously explored in the equal-access, universal Canadian health care system. The aim of this study is to compare whether socioeconomic status is associated with the type of treatment received (radical prostatectomy (RP) versus radiation therapy (RT)) for men diagnosed with nonmetastatic prostate cancer in Manitoba, Canada. Methods: Men who were diagnosed with non-metastatic prostate cancer between 2004 and 2016 and subsequently treated with RP or RT were identified using the CancerCare Manitoba Registry and linked to provincial databases. SES was defined as neighbourhood income by postal code and divided into income quintiles (Q1-Q5, with Q1 the lowest quintile and Q5 the highest). Multivariable logistic regression nested models were used to compare whether socioeconomic status was associated with treatment type received. Results: We identified 4,560 individuals between 2004-2016 who were diagnosed with non-metastatic prostate cancer. 2,554 men were treated with RP and 2,006 with RT.As income quintile increased, men were more likely to undergo RP than RT (Q3 vs Q1: aOR 1.45 (1.09-1.92); Q5 vs. Q1: aOR 2.17, 95% CI 1.52-2.86). Conclusions: Despite a universal health care system, socioeconomic inequities are present for men seeking primary treatment for prostate cancer. Further investigation into the decision making process among patients diagnosed with prostate cancer may inform decision making to ameliorate these disparities.


2007 ◽  
Vol 10 (6) ◽  
pp. A447
Author(s):  
D Crespo ◽  
R Parana ◽  
H Sette ◽  
H Cheinquer ◽  
F Barros ◽  
...  

1999 ◽  
Vol 15 (4) ◽  
pp. 619-628
Author(s):  
Yvonne G. Doyle ◽  
R. H. M. McNeilly

Eleven percent of the U.K. population holds private health care insurance, and £2.2 billion are spent annually in the acute sector of private health care. Although isolated from policy discussions about new medical technology in the National Health Service, the private sector encounters these interventions regularly. During 18 months in one company, a new medical technology was encountered on average every week; 59 leading edge technologies were submitted for authorization (18 on multiple occasions). There are certain constraints on purchasers of health care in the private sector in dealing with new technology; these include fragmentation of the sector, differing rationalities within companies about limitations on eligibility of new procedures while competing for business, the role and expertise of the medical adviser, and demands of articulate customers. A proactive approach by the private sector to these challenges is hampered by its independence. Poor communication between the public and private sectors, and the lack of a more inclusive approach to policy centrally, undermine the rational diffusion and use of new medical technology in the U.K. health care system.


Sign in / Sign up

Export Citation Format

Share Document